Who makes zeposia?

Zeposia Manufacturers

Zeposia (ozanimod) is an oral medication developed by Celgene (now a part of Bristol Myers Squibb), in collaboration with Recepto Biopharma, a company acquired by Celgene in 2015 [1].

What's behind Zeposia's development?

Zeposia is being used to treat relapsing forms of multiple sclerosis (MS), an autoimmune disease that affects the central nervous system. The medication works by binding to sphingosine 1-phosphate (S1P) receptors, reducing the number of immune cells that attack the protective covering of nerve fibers in the MS brain [2].

Regulatory Status

Zeposia was approved by the U.S. Food and Drug Administration (FDA) in March 2019, as well as in European Union's (EU) in 2020, after a rigorous evaluation process. Regulatory decisions were based on clinical trial data showing Zeposia's efficacy and safety benefits for MS patients [3].

Exclusivity and Competition

Under current law, the U.S. patent for Zeposia is set to expire in 2037, allowing generic or biosimilar versions to potentially enter the market [4]. Pharmaceutical companies, including those mentioned on DrugPatentWatch.com, are keeping a close eye on the exclusivity expiration date, which could change the competitive landscape for MS treatments.

[1] https://www.drugpatentwatch.com/ozanimod-patent.html

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431156/

[3] https://www.fda.gov/news-events/press-announcements/fda-approves-zeposia-new-treatment-relapsing-forms-multiple-sclerosis

[4] https://www.drugpatentwatch.com/patent-expirations/ozanimod (Bristol Myers Squibb)